Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Stock analysts at Lifesci Capital issued their FY2025 EPS estimates for shares of Tarsus Pharmaceuticals in a research note issued on Wednesday, February 26th. Lifesci Capital analyst C. Jubinville forecasts that the company will post earnings per share of ($1.65) for the year. The consensus estimate for Tarsus Pharmaceuticals' current full-year earnings is ($3.17) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals' Q4 2025 earnings at ($0.11) EPS.
Several other equities analysts also recently weighed in on TARS. Guggenheim reissued a "buy" rating and issued a $78.00 price target (up from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. The Goldman Sachs Group raised their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a research note on Friday, November 15th. Oppenheimer upped their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. Barclays reduced their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research report on Wednesday. Finally, HC Wainwright restated a "buy" rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a report on Wednesday. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Tarsus Pharmaceuticals presently has an average rating of "Buy" and an average price target of $61.33.
Get Our Latest Stock Analysis on Tarsus Pharmaceuticals
Tarsus Pharmaceuticals Price Performance
TARS stock traded up $0.93 during midday trading on Thursday, reaching $44.48. The stock had a trading volume of 845,617 shares, compared to its average volume of 643,241. Tarsus Pharmaceuticals has a 52-week low of $20.08 and a 52-week high of $57.28. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The company's fifty day simple moving average is $50.97 and its 200 day simple moving average is $43.25. The company has a market cap of $1.71 billion, a price-to-earnings ratio of -11.67 and a beta of 1.01.
Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The business had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million.
Institutional Investors Weigh In On Tarsus Pharmaceuticals
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Toronto Dominion Bank purchased a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth $105,714,000. GF Fund Management CO. LTD. purchased a new position in Tarsus Pharmaceuticals during the fourth quarter worth about $44,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. acquired a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter valued at about $3,278,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Tarsus Pharmaceuticals by 18.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 69,826 shares of the company's stock valued at $3,866,000 after acquiring an additional 10,991 shares during the period. Finally, Woodline Partners LP lifted its holdings in shares of Tarsus Pharmaceuticals by 52.3% in the 4th quarter. Woodline Partners LP now owns 108,986 shares of the company's stock worth $6,035,000 after acquiring an additional 37,417 shares during the last quarter. Hedge funds and other institutional investors own 90.01% of the company's stock.
About Tarsus Pharmaceuticals
(
Get Free Report)
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
See Also
Before you consider Tarsus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.
While Tarsus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
